Samsung Bioepis has been rapidly chasing Celltrion in the domestic biosimilar business and expanding sales in the market.

As of last year, domestic biosimilar sales of Samsung Bioepis and Celltrion were KRW 42.5 billion and KRW 69 billion, respectively. Samsung Bioepis’s sales more than tripled in one year, greatly narrowing the gap with Celltrion.

Samsung Bioepis has been copromoting sales of its biosimilar products in the domestic market with Boryung, Yuhan Corp, Samil Pharm, and Daewoong Pharmaceutical. Samsung Bioepis’s new product releases and the sales power of domestic pharmaceutical companies are analyzed to have created synergy and driven an increase in sales last year.